- Home
- AMLX vs KMDA Comparison
AMLX vs KMDA Comparison
Compare AMLX & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMLX
- KMDA
- Stock Information
- Founded
- AMLX 2014
- KMDA 1990
- Country
- AMLX United States
- KMDA Israel
- Employees
- AMLX N/A
- KMDA N/A
- Industry
- AMLX Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- AMLX Health Care
- KMDA Health Care
- Exchange
- AMLX Nasdaq
- KMDA Nasdaq
- Market Cap
- AMLX 330.5M
- KMDA 349.1M
- IPO Year
- AMLX 2022
- KMDA N/A
- Fundamental
- Price
- AMLX $4.92
- KMDA $6.47
- Analyst Decision
- AMLX Buy
- KMDA Strong Buy
- Analyst Count
- AMLX 4
- KMDA 3
- Target Price
- AMLX $8.50
- KMDA $14.67
- AVG Volume (30 Days)
- AMLX 815.5K
- KMDA 106.2K
- Earning Date
- AMLX 05-08-2025
- KMDA 05-07-2025
- Dividend Yield
- AMLX N/A
- KMDA 3.10%
- EPS Growth
- AMLX N/A
- KMDA 66.67
- EPS
- AMLX N/A
- KMDA 0.25
- Revenue
- AMLX $87,371,000.00
- KMDA $160,953,000.00
- Revenue This Year
- AMLX N/A
- KMDA $14.01
- Revenue Next Year
- AMLX N/A
- KMDA $9.24
- P/E Ratio
- AMLX N/A
- KMDA $25.58
- Revenue Growth
- AMLX N/A
- KMDA 12.93
- 52 Week Low
- AMLX $1.58
- KMDA $4.74
- 52 Week High
- AMLX $7.27
- KMDA $9.15
- Technical
- Relative Strength Index (RSI)
- AMLX 74.02
- KMDA 49.43
- Support Level
- AMLX $3.79
- KMDA $6.36
- Resistance Level
- AMLX $4.05
- KMDA $6.57
- Average True Range (ATR)
- AMLX 0.36
- KMDA 0.28
- MACD
- AMLX 0.12
- KMDA 0.06
- Stochastic Oscillator
- AMLX 98.37
- KMDA 76.23
About AMLX Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.